Browse the evidence

SGLT2 inhibitors reduce the incidence of atrial fibrillation (AF) and atrial flutter (AFL) by reducing atrial dilation, intracellular sodium/calcium levels, and epicardial adipose tissue.

Taking SGLT2 inhibitors may lower your risk of developing irregular heartbeats like atrial fibrillation, which is a common complication in diabetes and heart failure.

GLP-1 receptor agonists reduce stroke risk but do not significantly prevent the onset of atrial fibrillation or atrial flutter, and may increase heart rate.

GLP-1 RAs are effective at reducing stroke risk, but unlike SGLT2 inhibitors, they do not appear to prevent atrial fibrillation and may slightly increase heart rate.

GLP-1 receptor agonists (GLP-1 RAs) induce significant gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) by slowing gastric emptying and increasing gastric accommodation, with incidence rates ranging from 18% to 52% depending on the specific agent and dose.

If you are prescribed a GLP-1 drug like semaglutide or liraglutide, expect a high chance of nausea or vomiting, especially when starting. The paper advises starting at the lowest dose and increasing slowly. Crucially, you must adjust your diet: eat smaller meals, reduce fat, and avoid raw fiber. If you continue to have side effects, ask your doctor about dose de-escalation. Do not assume the sickness is what causes the weight loss; the drug works directly, but the side effects are a common hurdle to manage.

GLP-1 receptor agonists delay gastric emptying and increase gastric accommodation, which contributes to satiety but poses a significant risk of aspiration during perioperative procedures, necessitating specific preoperative management guidelines.

If you are having surgery and take a weekly GLP-1 shot (like Ozempic or Wegovy), tell your surgeon and anesthesiologist. For elective surgery, you may need to stop the drug 4 weeks beforehand. If it's an emergency, they will check your stomach with an ultrasound and may give you a drug (erythromycin) to empty it. This is a new standard of care to prevent choking on stomach contents during anesthesia.

Some GLP-1RAs (e.g., Lixisenatide, Exenatide, oral Semaglutide) show neutral cardiovascular outcomes in patients with Type 2 Diabetes, suggesting that not all GLP-1RAs provide cardiovascular protection.

Not all GLP-1 medications protect the heart. Drugs like Lixisenatide, Exenatide, and oral Semaglutide have shown neutral effects on major cardiovascular events in large studies. If you have heart disease, ask your doctor if your specific GLP-1 medication has proven cardiovascular benefits.

Anti-obesity medications (GLP-1 RAs, MC4R agonists) and bariatric surgery work by improving appetite control and resetting the fat mass set point, rather than just creating a caloric deficit.

Medications like GLP-1 agonists and surgeries like gastric bypass succeed because they fix the broken biological signals in your brain that tell you when to stop eating. They improve appetite control, making it easier to maintain weight loss without constant willpower.

Metformin treatment alters gut microbiota composition (increasing Escherichia coli, decreasing Intestinibacter bartlettii) to enhance the production of short-chain fatty acids (propionate and butyrate) and modulate bile acid pools, which mediates glucose-lowering effects.

If you take metformin, your gut bacteria are actively helping lower your blood sugar by producing beneficial fats (SCFAs) and signaling molecules. However, this same bacterial shift can cause stomach upset for about 30% of users. If you experience GI distress, it may be linked to this mechanism, and discussing management strategies with your provider is important.

Performing resistance exercise during the follicular phase (high estrogen) does not yield greater muscle protein synthesis or myofibrillar protein breakdown compared to the luteal phase (high progesterone) in naturally cycling women.

You do not need to schedule your resistance training around your menstrual cycle to maximize muscle growth. Whether you are in your follicular (high estrogen) or luteal (high progesterone) phase, your muscles respond to resistance exercise similarly in terms of protein synthesis and breakdown. Consistency in your training program is more important than trying to time your workouts with specific hormonal phases.

Integrating multiple computational gene prioritization methods (SMR, FINEMAP, DEPICT, MAGMA, TWAS, MSC, PoPS, nearest gene) identifies 292 high-confidence candidate genes associated with BMI, many of which regulate neuronal body weight control, circadian rhythm, insulin secretion, and glucose homeostasis.

This research does not offer a direct lifestyle intervention but highlights that obesity has strong genetic underpinnings involving brain regulation, insulin, and circadian rhythms. Understanding these specific biological pathways can help explain why weight loss is difficult for some and points toward future targeted therapies (e.g., drugs affecting GIPR or FGFR1) rather than just willpower-based approaches.

Combined pharmacological administration of oxytocin (OT) and a selective CCKAR agonist (A-71263) produces greater weight loss and fat mass reduction than either agent alone in diet-induced obese mice.

Combining oxytocin with a CCK receptor agonist is more effective for weight loss than using either drug alone. This suggests that future obesity treatments might need to target multiple pathways simultaneously to overcome diet-induced resistance.

GLP-1RAs exert their therapeutic effects through complex intracellular signaling pathways, specifically activating ERK1/2, AMPK, cAMP, MAPK, and PKC, which regulate insulin secretion, cell proliferation, and inflammation.

The effectiveness of GLP-1 medications is driven by their ability to activate specific cellular pathways (ERK1/2, AMPK, cAMP, MAPK, PKC). These pathways control insulin release, cell growth, and inflammation, which is why these drugs work for both diabetes and potentially other conditions like cancer or cardiovascular disease.

GLP-1 receptor agonists delay gastric emptying, increasing the risk of pulmonary aspiration during anesthesia, necessitating specific perioperative holding periods or gastric assessment before elective surgery.

If you are taking a GLP-1 weight loss drug (like Ozempic or Wegovy) and need elective surgery, tell your surgeon and anesthesiologist immediately. These drugs slow down your stomach, which can cause dangerous aspiration during anesthesia. You may need to hold your medication for 1-3 weeks before surgery, or your surgery might be postponed until your stomach is empty. Do not skip doses without consulting your care team, as this can affect your blood sugar and weight management.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACEs) and all-cause mortality in patients with type 2 diabetes, independent of glycemic control, through anti-inflammatory and plaque-stabilizing mechanisms.

If you have type 2 diabetes and high cardiovascular risk, GLP-1RAs like semaglutide or liraglutide can significantly reduce your risk of heart attack, stroke, and death. This benefit comes from stabilizing plaque and reducing inflammation, not just lowering blood sugar. Discuss these options with your doctor, especially if you have existing heart disease.

Metformin treatment alters gut microbiota composition (increasing Escherichia coli and decreasing Intestinibacter bartlettii) to enhance the production of short-chain fatty acids (propionate and butyrate) and modulate bile acid pools, which mediates glucose-lowering effects.

If you take metformin, your gut bacteria are actively helping lower your blood sugar by producing beneficial fatty acids. This is a key part of how the drug works, though it can cause temporary stomach upset for some people.

GLP-1 receptor agonists lower serum TSH levels in patients with Type 2 Diabetes, particularly those who experience weight loss, without necessarily changing free thyroxine (FT4) levels, suggesting a mechanism involving central nervous system GLP-1 receptors or improved thyroid hormone sensitivity.

If your TSH levels drop while on a GLP-1 medication, it is likely due to your weight loss or improved metabolic sensitivity, not necessarily a thyroid problem. Your doctor will likely check your Free T4 to ensure your thyroid function is normal. This change is generally considered a positive metabolic adaptation rather than a disease state.

The peptide drug GUB021794, a GLP-1 receptor agonist derived from a secretin backbone, promotes dose-dependent body weight loss in diet-induced obese mice comparable to the clinically approved drug semaglutide.

This research identifies a new peptide drug, GUB021794, which mimics the hormone GLP-1 to reduce appetite and body weight. In obese mice, it worked as well as the popular drug semaglutide but was designed to last longer in the body, allowing for once-weekly dosing instead of daily. This suggests a potential future treatment option for obesity that offers similar weight loss benefits with less frequent administration.

Adults with diabetes and overweight/obesity are significantly more likely to use weight-inducing (WI) medications than weight-reducing (WR) medications, with WI use being 4 to 20 times higher than WR use, despite clinical guidelines recommending preferential use of WR agents.

If you have diabetes and are overweight, your current medication might be working against your weight loss goals. Many common diabetes drugs cause weight gain. Ask your doctor about switching to weight-reducing options like GLP-1 agonists or SGLT2 inhibitors, which are now recommended for people with your profile. Be aware that these drugs can be expensive and may require injections, but they are designed to help you lose weight, unlike older medications.

Long-term use of GLP-1 receptor agonists (≥78 weeks) significantly increases the risk of deep vein thrombosis (DVT) compared to placebo or other anti-diabetic drugs.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Victoza) for more than a year, be aware that your risk of deep vein thrombosis (DVT) is higher than if you were not taking it. This risk is most notable in people with existing cardiovascular disease. However, the absolute increase in risk is small. Discuss any history of blood clots with your doctor before starting or continuing long-term therapy.

Overall Venous Thromboembolism (VTE) risk is not significantly increased by GLP-1RA use, as the increase in DVT is offset by no change in Pulmonary Embolism (PE) risk.

Taking GLP-1 medications does not significantly increase your overall risk of blood clots (VTE) when looking at the big picture. While there is a small, non-significant upward trend, it is not statistically proven to be dangerous for the general population. The specific risk of DVT is only significant with very long-term use.

SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors provide cardiovascular organ protection in type 2 diabetes through direct antioxidant and anti-inflammatory mechanisms, independent of glucose lowering.

If you have Type 2 Diabetes, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These drugs do more than just lower blood sugar; they actively protect your heart and kidneys by reducing inflammation and oxidative stress, which are major drivers of heart disease in diabetic patients.

GLP-1 receptor agonists reduce platelet aggregation and thrombus formation, thereby mitigating the risk of thrombotic cardiovascular events in diabetic patients.

GLP-1 agonists may help prevent blood clots by making platelets less sticky, which adds to their heart-protective benefits beyond just sugar control.

Intestinal deficiency of Acyl-CoA synthetase 5 (ACSL5) reduces food intake and protects against diet-induced obesity by increasing postprandial secretion of GLP-1 and PYY.

This research suggests that how your body processes dietary fat in the intestine—specifically through the enzyme ACSL5—can influence your hunger hormones (GLP-1 and PYY). When this process is altered, it can lead to increased feelings of fullness and reduced food intake, potentially protecting against weight gain on high-fat diets. While this is a genetic mechanism in mice, it highlights the importance of gut hormones in regulating appetite and energy balance.

Semaglutide (2.4 mg weekly) induces MASH resolution in patients with stage 2-3 fibrosis, though it does not significantly improve fibrosis itself.

Semaglutide 2.4 mg weekly is highly effective at resolving active liver inflammation (MASH) in patients with moderate fibrosis. However, it does not reverse the scarring (fibrosis) itself. Patients should expect significant weight loss and metabolic improvement, but should not assume their liver scarring will disappear with this drug alone.

Statins reduce the risk of developing MASLD and progression to liver fibrosis, and may reduce cardiovascular events in MASLD patients, despite not directly reducing liver fat.

If you have fatty liver and high cardiovascular risk, you should take statins. They do not remove liver fat, but they reduce inflammation and fibrosis, and significantly lower your risk of heart attacks and strokes. The benefits outweigh the theoretical risks.